Journal Article
. 2014 Nov;33(1).
doi: 10.1200/JCO.2014.56.3296.

SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer

George T Budd 1 William E Barlow 2 Halle C F Moore 2 Timothy J Hobday 2 James A Stewart 2 Claudine Isaacs 2 Muhammad Salim 2 Jonathan K Cho 2 Kristine J Rinn 2 Kathy S Albain 2 Helen K Chew 2 Gary V Burton 2 Timothy D Moore 2 Gordan Srkalovic 2 Bradley A McGregor 2 Lawrence E Flaherty 2 Robert B Livingston 2 Danika L Lew 2 Julie R Gralow 2 Gabriel N Hortobagyi 2 
Affiliations
  • PMID: 25422488
  •     16 References
  •     34 citations

Abstract

Purpose: To determine the optimal dose and schedule of anthracycline and taxane administration as adjuvant therapy for early-stage breast cancer.

Patients And Methods: A 2 × 2 factorial design was used to test two hypotheses: (1) that a novel continuous schedule of doxorubicin-cyclophosphamide was superior to six cycles of doxorubicin-cyclophosphamide once every 2 weeks and (2) that paclitaxel once per week was superior to six cycles of paclitaxel once every 2 weeks in patients with node-positive or high-risk node-negative early-stage breast cancer. With 3,250 patients, a disease-free survival (DFS) hazard ratio of 0.82 for each randomization could be detected with 90% power with two-sided α = .05. Overall survival (OS) was a secondary outcome.

Results: Interim analyses crossed the futility boundaries for demonstrating superiority of both once-per-week regimens and once-every-2-weeks regimens. After a median follow-up of 6 years, a significant interaction developed between the two randomization factors (DFS P = .024; OS P = .010) in the 2,716 patients randomly assigned in the original design, which precluded interpretation of the two factors separately. Comparing all four arms showed a significant difference in OS (P = .040) but not in DFS (P = .11), with all treatments given once every 2 weeks associated with the highest OS. This difference in OS seemed confined to patients with hormone receptor-negative/human epidermal growth factor receptor 2 (HER2) -negative tumors (P = .067), with no differences seen with hormone receptor-positive/HER2-negative (P = .90) or HER2-positive tumors (P = .40).

Conclusion: Patients achieved a similar DFS with any of these regimens. Subset analysis suggests the hypothesis that once-every-2-weeks dosing may be best for patients with hormone receptor-negative/HER2-negative tumors.

Weekly paclitaxel in the adjuvant treatment of breast cancer.
Joseph A Sparano, Molin Wang, +7 authors, Nancy E Davidson.
N Engl J Med, 2008 Apr 19; 358(16). PMID: 18420499    Free PMC article.
Highly Cited.
Adjuvant chemotherapy in older women with early-stage breast cancer.
Hyman B Muss, Donald A Berry, +23 authors, CALGB Investigators.
N Engl J Med, 2009 May 15; 360(20). PMID: 19439741    Free PMC article.
Highly Cited.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012.
Georgiana K Ellis, William E Barlow, +6 authors, Robert B Livingston.
J Clin Oncol, 2011 Jan 12; 29(8). PMID: 21220618    Free PMC article.
Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221).
Lara E Sucheston, Hua Zhao, +18 authors, Christine B Ambrosone.
Breast Cancer Res Treat, 2011 Jul 19; 130(3). PMID: 21766209    Free PMC article.
Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Heikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, +17 authors, Henrik Lindman.
J Clin Oncol, 2011 Nov 23; 30(1). PMID: 22105826
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.
Lawrence N Shulman, Constance T Cirrincione, +12 authors, Clifford Hudis.
J Clin Oncol, 2012 Jul 25; 30(33). PMID: 22826271    Free PMC article.
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Sandra M Swain, Gong Tang, +17 authors, Norman Wolmark.
J Clin Oncol, 2013 Aug 14; 31(26). PMID: 23940225    Free PMC article.
Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer.
S Yao, L E Sucheston, +18 authors, C B Ambrosone.
Pharmacogenomics J, 2013 Sep 04; 14(3). PMID: 23999597    Free PMC article.
Dose-dense anthracycline-based chemotherapy for node-positive breast cancer.
Georgiana K Ellis, Robert B Livingston, +2 authors, Tove Thompson.
J Clin Oncol, 2002 Aug 31; 20(17). PMID: 12202664
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Marc L Citron, Donald A Berry, +18 authors, Larry Norton.
J Clin Oncol, 2003 Apr 02; 21(8). PMID: 12668651
Highly Cited.
Risk factors for doxorubicin-induced congestive heart failure.
D D Von Hoff, M W Layard, +4 authors, F M Muggia.
Ann Intern Med, 1979 Nov 01; 91(5). PMID: 496103
Highly Cited.
Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity.
R T Chlebowski, W S Paroly, +4 authors, J R Bateman.
Cancer Treat Rep, 1980 Jan 01; 64(1). PMID: 7379058
Group sequential procedures: calendar versus information time.
D L Demets.
Stat Med, 1989 Oct 01; 8(10). PMID: 2814068
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Current treatment of early breast cancer: adjuvant and neoadjuvant therapy.
Elizabeth Miller, Hee Jin Lee, +3 authors, Bora Lim.
F1000Res, 2014 Nov 18; 3. PMID: 25400908    Free PMC article.
Review.
Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.
S Gandhi, G G Fletcher, +4 authors, M E Trudeau.
Curr Oncol, 2015 Apr 08; 22(Suppl 1). PMID: 25848343    Free PMC article.
Review.
Progress in adjuvant chemotherapy for breast cancer: an overview.
Jesus Anampa, Della Makower, Joseph A Sparano.
BMC Med, 2015 Aug 19; 13. PMID: 26278220    Free PMC article.
Highly Cited. Review.
The Globalization of Cooperative Groups.
Manuel Valdivieso, Benjamin W Corn, +8 authors, Charles D Blanke.
Semin Oncol, 2015 Oct 05; 42(5). PMID: 26433551    Free PMC article.
Review.
Comparison of toxicity profile and tolerability between two standard of care paclitaxel-based adjuvant chemotherapy regimens in breast cancer.
Mohamed Alsharedi, Todd Gress, +2 authors, Maria Tria Tirona.
Med Oncol, 2016 Feb 18; 33(3). PMID: 26883934
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients.
Volker Möbus.
Breast Care (Basel), 2016 Apr 07; 11(1). PMID: 27051389    Free PMC article.
Review.
Review of the Reporting of Survival Analyses within Randomised Controlled Trials and the Implications for Meta-Analysis.
Sarah Batson, Gemma Greenall, Pollyanna Hudson.
PLoS One, 2016 May 07; 11(5). PMID: 27149107    Free PMC article.
Review.
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.
Z A Nahleh, W E Barlow, +11 authors, G N Hortobagyi.
Breast Cancer Res Treat, 2016 Jul 10; 158(3). PMID: 27393622    Free PMC article.
Developmental therapeutics for inflammatory breast cancer: Biology and translational directions.
Ricardo Costa, Cesar A Santa-Maria, +5 authors, Massimo Cristofanilli.
Oncotarget, 2016 Dec 08; 8(7). PMID: 27926493    Free PMC article.
Review.
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
Tessa G Steenbruggen, Mette S van Ramshorst, +3 authors, Gabe S Sonke.
Drugs, 2017 Jun 16; 77(12). PMID: 28616845
Review.
Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience.
Marcus Vetter, Spyridon Fokas, +6 authors, Rosanna Zanetti-Dällenbach.
Oncotarget, 2017 Nov 02; 8(43). PMID: 29088896    Free PMC article.
Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study.
Liheng Zhou, Shuguang Xu, +7 authors, Jinsong Lu.
Oncotarget, 2017 Nov 08; 8(45). PMID: 29108309    Free PMC article.
Efficacy, safety and proper dose analysis of PEGylated granulocyte colony-stimulating factor as support for dose-dense adjuvant chemotherapy in node positive Chinese breast cancer patients.
Fan Zhang, RuiXia LingHu, +5 authors, Junlan Yang.
Oncotarget, 2017 Nov 08; 8(45). PMID: 29108384    Free PMC article.
Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci.
Lara E Sucheston-Campbell, Alyssa I Clay-Gilmour, +23 authors, Christine B Ambrosone.
Pharmacogenet Genomics, 2017 Dec 27; 28(2). PMID: 29278617    Free PMC article.
Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP Study.
Gary R Zirpoli, Susan E McCann, +14 authors, Christine B Ambrosone.
J Natl Cancer Inst, 2018 Mar 17; 109(12). PMID: 29546345    Free PMC article.
Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials.
Dawn L Hershman, Cathee Till, +4 authors, Joseph M Unger.
J Clin Oncol, 2018 Mar 28; 36(26). PMID: 29584550    Free PMC article.
Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy.
Yihan Sun, Jae Hyun Kim, +6 authors, Daniel L Hertz.
Breast Cancer Res Treat, 2018 Jun 28; 171(3). PMID: 29946863    Free PMC article.
Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials.
Wenqi Zhou, Shizhe Chen, Faliang Xu, Xiaohua Zeng.
World J Surg Oncol, 2018 Jul 17; 16(1). PMID: 30007402    Free PMC article.
Review.
Cardio-oncology: protecting the heart from curative breast cancer treatment.
Jenica N Upshaw.
Gland Surg, 2018 Sep 04; 7(4). PMID: 30175052    Free PMC article.
Review.
Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221).
Jennifer M Mongiovi, Gary R Zirpoli, +14 authors, Susan E McCann.
Breast Cancer Res, 2018 Nov 30; 20(1). PMID: 30486865    Free PMC article.
Taxanes for adjuvant treatment of early breast cancer.
Melina L Willson, Lucinda Burke, +3 authors, Nicholas Wilcken.
Cochrane Database Syst Rev, 2019 Sep 03; 9. PMID: 31476253    Free PMC article.
Systematic Review.
Inclusiveness and ethical considerations for observational, translational, and clinical cancer health disparity research.
Michael Behring, Kevin Hale, +3 authors, Upender Manne.
Cancer, 2019 Sep 11; 125(24). PMID: 31502259    Free PMC article.
Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy.
Daniel L Hertz, Kelley M Kidwell, +9 authors, N Lynn Henry.
Clin Cancer Res, 2018 Apr 29; 24(15). PMID: 29703818    Free PMC article.
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2019 Feb 12; 393(10179). PMID: 30739743    Free PMC article.
Highly Cited.
Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221).
Christine B Ambrosone, Gary R Zirpoli, +17 authors, Kathy S Albain.
J Clin Oncol, 2019 Dec 20; 38(8). PMID: 31855498    Free PMC article.
Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy.
Lauren A Marcath, Kelley M Kidwell, +10 authors, Daniel L Hertz.
Br J Clin Pharmacol, 2019 Dec 12; 86(5). PMID: 31823378    Free PMC article.
Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy.
Elvira C van Dalen, Helena J H van der Pal, Leontien C M Kremer.
Cochrane Database Syst Rev, 2016 Mar 05; 3. PMID: 26938118    Free PMC article.
Systematic Review.
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
Junjie Li, Keda Yu, +37 authors, CBCSG010 Study Group.
J Clin Oncol, 2020 Apr 11; 38(16). PMID: 32275467    Free PMC article.
Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study.
Ines Vaz-Luis, Romualdo Barroso-Sousa, +18 authors, Nancy U Lin.
J Clin Oncol, 2020 Apr 25; 38(21). PMID: 32330102    Free PMC article.
Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer.
Qing Li, Jiani Wang, +9 authors, Binghe Xu.
Chin J Cancer Res, 2020 Sep 24; 32(4). PMID: 32963461    Free PMC article.
Adjuvant Dose-Dense Chemotherapy for Breast Cancer: Available Evidence and Recent Updates.
Fernando Kude de Almeida, Daniela Dornelles Rosa.
Breast Care (Basel), 2019 Feb 26; 13(6). PMID: 30800040    Free PMC article.
Review.
Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival.
Rikki A Cannioto, Alan Hutson, +18 authors, Christine B Ambrosone.
J Natl Cancer Inst, 2020 Apr 03; 113(1). PMID: 32239145    Free PMC article.
The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
Xingfa Huo, Jinming Li, +5 authors, Jiuda Zhao.
BMC Cancer, 2021 Jan 21; 21(1). PMID: 33468087    Free PMC article.
Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy on pathologic complete response rate in HER2-negative breast cancer patients.
M E Tesch, S K Chia, C E Simmons, N LeVasseur.
Breast Cancer Res Treat, 2021 Feb 22;. PMID: 33611678